IHS Chemical Week

EnviroTech :: Regulatory :: Regulatory: Legal

FDA Issues Warning Letter to Lonza Plant in U.S.

1:19 AM MDT | September 14, 2011 | Deepti Ramesh

The U.S. Food and Drug Administration (FDA) issued a warning letter earlier this month to Lonza’s manufacturing plant at Hopkinton, MA, for deviating from current good manufacturing practice (cGMP). An FDA inspection from April 4, 2011 to May 6, 2011 at Lonza’s pharmaceutical and active pharmaceutical ingredient (API) manufacturing facility at Hopkinton identified significant violations of cGMP regulations for finished pharmaceuticals, and from cGMP for the manufacture of APIs, FDA says. Lonza responded on May 26, 2011 and the FDA says it has reviewed...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa